Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience
E.S. Lutrino(Ospedale A. Perrino), Saverio Cinieri(Ospedale A. Perrino), Giovanna Giordano(Brigham and Women's Hospital), Gianfranco Filippelli(Presidio Ospedaliero), G. Dima, Palma Fedele(Ospedale A. Perrino), Marianna Giampaglia(Ospedale San Carlo), Chiara Caliolo(Ospedale A. Perrino), Antonio Febbraro(Fatebenefratelli Hospital), Maria Enrica(Ospedale A. Perrino), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Laura Orlando, Caterina Fontanella(Centro di Riferimento Oncologico), Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), A. Quaranta(Ospedale A. Perrino), C. Scavelli(ASST Fatebenefratelli Sacco), P. Schiavone, Claudio Zamagni(Policlinico S.Orsola-Malpighi)
Cited by 1
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234